Assessing paclitaxel-coated vs sirolimus-coated balloon angioplasty for coronary artery diseases: A systematic review and meta-analysis

Table 1 Baseline characteristics of included studies

Ref.	Sample size: Paclitaxel	Sample size: Sirolimus	Follow-up duration (months)	Age (years)		Male		Hypertension		Diabetes		Dyslipidemia		Prior MI		ACS presentation
				Paclitaxel, mean	Sirolimus, mean	Paclitaxel (%)	Sirolimus (%)	Paclitaxel (%)	Sirolimus (%)	Paclitaxel (%)	Sirolimus (%)	Paclitaxel (%)	Sirolimus (%)	Paclitaxel (%)	Sirolimus (%)	Paclitaxel (%)	Sirolimus (%)
Liu et al[23], 2025	128	130	12	63.7	63.8	75.8	73.1	70.3	66.9	41.4	33.8	14.1	17.7	6.3	4.6	89	92.3
Scheller et al[24], 2024	35	35	12	67	66	77	86	89	83	43	31	71	77	34	37	NR	NR
Ali et al[16], 2019	25	25	12	58.6	61.6	76	88	92	96	76	72	84	92	36	32	NR	NR
Cortese et al[17], 2021	290	290	12	67	66	75	77	69	74	35	45	61	67	43	48	52	53
Scheller et al[18], 2022	51	50	12	63	67	76	86	94	98	59	54	84	88	55	56	90	94
Ahmad et al[22], 2022	35	35	12	59	60	86	74	66	69	49	54	57	51	46	34	NR	NR
Ninomiya et al[19], 2023	60	61	6	66	69	83	90	73	84	25	25	82	82	33	28	NR	NR
Briguori et al[20], 2023	186	186	12	68	67	77	75	92	90	55	56	90	86	25	21	25	25
Cuculi et al[21], 2023	139	220	12	66	67	NR	NR	NR	NR	25	33	NR	NR	NR	NR	41	40

MI: Myocardial infarction; ACS: Acute coronary syndrome; NR: Not reported.